Suppr超能文献

全身照射或全骨髓照射造血干细胞移植后继发恶性肿瘤的风险:早期随访的见解。

Risk of Subsequent Malignant Neoplasms Following Hematopoietic Stem Cell Transplantation with Total Body Irradiation or Total Marrow Irradiation: Insights from Early Follow-Up.

机构信息

Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California.

Department of Population Sciences, City of Hope National Medical Center, Duarte, California.

出版信息

Transplant Cell Ther. 2022 Dec;28(12):860.e1-860.e6. doi: 10.1016/j.jtct.2022.09.013. Epub 2022 Sep 24.

Abstract

Total marrow irradiation (TMI) is an alternative to total body irradiation (TBI) as a component of the conditioning regimen for hematopoietic cell transplantation (HCT), offering the ability to deliver more targeted doses and facilitating organ-sparing. The organ-sparing effect of TMI is theorized to decrease the risk of complications associated with radiation, including subsequent malignant neoplasms (SMNs), while allowing for dosage escalation to improve oncologic outcomes. The purpose of this study was to compare SMNs rates among patients treated with TBI- or TMI-based conditioning regimens. We hypothesized that TMI would yield a rate of SMNs comparable to, if not lower than, TBI. A retrospective matched-pair analysis of patients who underwent allogeneic HCT and received either TBI- or TMI-based conditioning regimens to a total dose of 12 to 20 Gy was performed. A total of 171 patients received TMI-based conditioning and 171 received TBI-based conditioning, matched based on age, sex, diagnosis, and length of follow-up. SMNs were identified from an established long-term follow-up protocol, our institutional cancer registry, and the California Cancer Registry. There were no significant differences in patient and clinical characteristics between the TMI and TBI cohorts except for clinical response status at transplantation and radiation dose. As expected, patients in the TMI received higher radiation doses (median dose, 16.0 Gy for the TMI cohort versus 13.2 Gy for the TBI cohort; P < .001). The median follow-up for both cohorts was 2.0 years (range, .5 to 12.3 years). There was no significant difference in the risk of developing SMNs between the 2 cohorts (P = .81). A total of 9 patients (5.3%) conditioned with TBI and 10 patients (5.8%) conditioned with TMI developed SMNs, at a median of 3.3 years and 1.7 years following HCT, respectively. Excluding nonmelanoma skin cancers and noninvasive neoplasms, 2 patients in the TBI cohort developed SMNs (both melanomas), and 1 patient in the TMI cohort developed an SMN (colon cancer). No patients developed a subsequent hematologic malignancy. TMI-based conditioning is not associated with a significant difference in the risk of developing SMNs compared with TBI-based conditioning during early post-HCT follow-up. Future studies with longer follow-up may be needed to further characterize the risk of SMNs associated with TMI-based conditioning regimens compared with TBI-based regimens.

摘要

全骨髓照射(TMI)是全身照射(TBI)作为造血细胞移植(HCT)预处理方案的替代方法,具有提供更靶向剂量的能力,并有利于器官保存。TMI 的器官保存作用理论上可以降低与辐射相关的并发症的风险,包括随后的恶性肿瘤(SMN),同时允许剂量升级以改善肿瘤学结果。本研究的目的是比较 TBI 或 TMI 为基础的预处理方案治疗患者的 SMN 发生率。我们假设 TMI 的 SMN 发生率与 TBI 相似,如果不低于 TBI。对接受 12 至 20 Gy 总剂量的 TBI 或 TMI 为基础的预处理方案进行同种异体 HCT 并接受治疗的患者进行了回顾性配对分析。共 171 例患者接受 TMI 为基础的预处理,171 例接受 TBI 为基础的预处理,根据年龄、性别、诊断和随访时间进行匹配。SMN 通过既定的长期随访方案、我们的机构癌症登记处和加利福尼亚癌症登记处确定。TMI 和 TBI 两组患者的患者和临床特征除移植时临床反应状态和辐射剂量外无显著差异。正如预期的那样,TMI 组患者接受的辐射剂量更高(TMI 组中位数剂量为 16.0 Gy,TBI 组中位数剂量为 13.2 Gy;P<.001)。两组患者的中位随访时间均为 2.0 年(范围为 0.5 至 12.3 年)。两组患者发生 SMN 的风险无显著差异(P=0.81)。9 例(5.3%)接受 TBI 预处理的患者和 10 例(5.8%)接受 TMI 预处理的患者分别在 HCT 后 3.3 年和 1.7 年发生 SMN。排除非黑色素瘤皮肤癌和非侵袭性肿瘤后,TBI 组有 2 例患者发生 SMN(均为黑色素瘤),TMI 组有 1 例患者发生 SMN(结肠癌)。无患者发生后续血液系统恶性肿瘤。与 TBI 为基础的预处理相比,在 HCT 后早期随访期间,TMI 为基础的预处理与 SMN 发生风险无显著差异。可能需要进行随访时间更长的未来研究,以进一步描述 TMI 为基础的预处理方案与 TBI 为基础的方案相比与 SMN 相关的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验